NeuroPace
The neurostimulation device, which is currently for investigational use only, aims to treat cognitive and functional decline in Alzheimer's patients.
The new portal helps collect and offer insights about a patient's seizure data in real-time.
The nearly 14-year-old company hopes to raise $75 million to support its implanted, closed-loop seizure prevention system.
The company's implanted product acts as a closed-loop system that monitors and responds to brain activity by automatically delivering stimulation prior to the start of a seizure.